Literature DB >> 26577938

Diagnostic value of combining ¹¹C-choline and ¹⁸F-FDG PET/CT in hepatocellular carcinoma.

Maria-Angéla Castilla-Lièvre1,2, Dominique Franco3, Philippe Gervais4,5, Bertrand Kuhnast4,5, Hélène Agostini6, Lysiane Marthey7, Serge Désarnaud4,5, Badia-Ourkia Helal4,5.   

Abstract

PURPOSE: In this prospective study, our goal was to emphasize the diagnostic value of combining (11)C-choline and (18)F-FDG PET/CT for hepatocellular carcinoma (HCC) in patients with chronic liver disease.
METHODS: Thirty-three consecutive patients were enrolled. All patients were suspected to have HCC based on CT and/or MRI imaging. A final diagnosis was obtained by histopathological examination or by imaging alone according to American Association for the Study of Liver Disease criteria. All patients underwent PET/CT with both tracers within a median of 5 days. All lesions showing higher tracer uptake than normal liver were considered positive for HCC. We examined how tracer uptake was related to biological (serum α-fetoprotein levels) and pathological (differentiation status, peritumoral capsule and vascular invasion) prognostic markers of HCC, as well as clinical observations at 6 months (recurrence and death).
RESULTS: Twenty-eight HCC, four cholangiocarcinomas and one adenoma were diagnosed. In the HCC patients, the sensitivity of (11)C-choline, (18)F-FDG and combined (11)C-choline and (18)F-FDG PET/CT for the detection of HCC was 75 %, 36 % and 93 %, respectively. Serum α-fetoprotein levels >200 ng/ml were more frequent among patients with (18)F-FDG-positive lesions than those with (18)F-FDG-negative lesions (p < 0.05). Early recurrence (n=2) or early death (n=5) occurred more frequently in patients with (18)F-FDG-positive lesions than in those with (18)F-FDG-negative lesions (p < 0.05).
CONCLUSION: The combined use of (11)C-choline and (18)F-FDG PET/CT detected HCC with high sensitivity. This approach appears to be of potential prognostic value and may facilitate the selection of patients for surgical resection or liver transplantation.

Entities:  

Keywords:  11C-Choline; 18F-FDG; Cirrhosis; Hepatocellular carcinoma; PET/CT

Mesh:

Substances:

Year:  2015        PMID: 26577938     DOI: 10.1007/s00259-015-3241-0

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


  21 in total

1.  18F-fluorodeoxyglucose PET/CT predicts tumour progression after transarterial chemoembolization in hepatocellular carcinoma.

Authors:  Myeong Jun Song; Si Hyun Bae; Sung Won Lee; Do Sun Song; Hee Yeon Kim; Ie Ryung Yoo; Joon-Il Choi; Young June Lee; Ho Jong Chun; Hae Giu Lee; Jong Young Choi; Seung Kew Yoon
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-02-22       Impact factor: 9.236

2.  A pilot comparison of 18F-fluorodeoxyglucose and 18F-fluorocholine PET/CT to predict early recurrence of unifocal hepatocellular carcinoma after surgical resection.

Authors:  Laetitia Fartoux; Sona Balogova; Valérie Nataf; Khaldoun Kerrou; Virginie Huchet; Olivier Rosmorduc; Jean-Noël Talbot
Journal:  Nucl Med Commun       Date:  2012-07       Impact factor: 1.690

3.  Positron emission tomography scanning in the evaluation of hepatocellular carcinoma.

Authors:  M A Khan; C S Combs; E M Brunt; V J Lowe; M K Wolverson; H Solomon; B T Collins; A M Di Bisceglie
Journal:  J Hepatol       Date:  2000-05       Impact factor: 25.083

4.  Detection of hepatocellular carcinoma with PET/CT: a prospective comparison of 18F-fluorocholine and 18F-FDG in patients with cirrhosis or chronic liver disease.

Authors:  Jean-Noël Talbot; Laetitia Fartoux; Sona Balogova; Valérie Nataf; Khaldoun Kerrou; Fabrice Gutman; Virginie Huchet; David Ancel; Jean-Didier Grange; Olivier Rosmorduc
Journal:  J Nucl Med       Date:  2010-10-18       Impact factor: 10.057

5.  Diagnostic role of radiolabelled choline PET or PET/CT in hepatocellular carcinoma: a systematic review and meta-analysis.

Authors:  Francesco Bertagna; Mattia Bertoli; Giovanni Bosio; Giorgio Biasiotto; Ramin Sadeghi; Raffaele Giubbini; Giorgio Treglia
Journal:  Hepatol Int       Date:  2014-09-03       Impact factor: 6.047

6.  11C-acetate and 18F-FDG PET/CT for clinical staging and selection of patients with hepatocellular carcinoma for liver transplantation on the basis of Milan criteria: surgeon's perspective.

Authors:  Tan To Cheung; Chi Lai Ho; Chung Mau Lo; Sirong Chen; See Ching Chan; Kenneth S H Chok; James Y Fung; Albert Chi Yan Chan; William Sharr; Thomas Yau; Ronnie T P Poon; Sheung Tat Fan
Journal:  J Nucl Med       Date:  2013-01-15       Impact factor: 10.057

7.  11C-acetate PET imaging in hepatocellular carcinoma and other liver masses.

Authors:  Chi-Lai Ho; Simon C H Yu; David W C Yeung
Journal:  J Nucl Med       Date:  2003-02       Impact factor: 10.057

8.  Role of ¹⁸F-FDG PET CT as an independent prognostic indicator in patients with hepatocellular carcinoma.

Authors:  Vineet Pant; Ishita B Sen; Arvinder S Soin
Journal:  Nucl Med Commun       Date:  2013-08       Impact factor: 1.690

9.  (18)F-FDG-PET/CT predicts early tumor recurrence in living donor liver transplantation for hepatocellular carcinoma.

Authors:  Seung Duk Lee; Seong Hoon Kim; Young-Kyu Kim; Chulhan Kim; Seok-Ki Kim; Sung-Sik Han; Sang-Jae Park
Journal:  Transpl Int       Date:  2012-10-25       Impact factor: 3.782

10.  Management of hepatocellular carcinoma: an update.

Authors:  Jordi Bruix; Morris Sherman
Journal:  Hepatology       Date:  2011-03       Impact factor: 17.425

View more
  13 in total

Review 1.  Morphological, dynamic and functional characteristics of liver pseudolesions and benign lesions.

Authors:  Matteo Renzulli; Nicolò Brandi; Giulia Argalia; Stefano Brocchi; Andrea Farolfi; Stefano Fanti; Rita Golfieri
Journal:  Radiol Med       Date:  2022-01-13       Impact factor: 3.469

2.  PET imaging of hepatocellular carcinoma by targeting tumor-associated endothelium using [68Ga]Ga-PSMA-617.

Authors:  Qiaomiao Lu; Yu Long; Kevin Fan; Zhiwen Shen; Yongkang Gai; Qingyao Liu; Dawei Jiang; Weibo Cai; Chidan Wan; Xiaoli Lan
Journal:  Eur J Nucl Med Mol Imaging       Date:  2022-06-28       Impact factor: 10.057

3.  GPC3-targeted immunoPET imaging of hepatocellular carcinomas.

Authors:  Shuxian An; Di Zhang; You Zhang; Cheng Wang; Liang Shi; Weijun Wei; Gang Huang; Jianjun Liu
Journal:  Eur J Nucl Med Mol Imaging       Date:  2022-02-11       Impact factor: 10.057

4.  The Clinical Implications of Liver Resection Margin Size in Patients with Hepatocellular Carcinoma in Terms of Positron Emission Tomography Positivity.

Authors:  Jae Hyun Park; Dong Hwi Kim; Sung Hoon Kim; Moon Young Kim; Soon Koo Baik; In Su Hong
Journal:  World J Surg       Date:  2018-05       Impact factor: 3.352

5.  Perfusion CT and PET with 18F-FDG and 18F-FCh in the complex diagnosis of hepatocellular carcinoma.

Authors:  P E Tulin; M B Dolgushin; A A Odzharova; A I Mikhaylov; B M Medvedeva; S V Shiryaev; B I Dolgushin
Journal:  Eur J Hybrid Imaging       Date:  2017-12-01

6.  Predicting tumor recurrence using metabolic indices of 18F-FDG PET/CT prior to orthotopic liver transplantationfor hepatocellular carcinoma.

Authors:  Enci Ding; Dongyan Lu; Lijuan Wei; Xuemin Feng; Jie Shen; Wengui Xu
Journal:  Oncol Lett       Date:  2020-05-28       Impact factor: 2.967

Review 7.  State of the art in magnetic resonance imaging of hepatocellular carcinoma.

Authors:  Natally Horvat; Serena Monti; Brunna Clemente Oliveira; Camila Carlos Tavares Rocha; Romina Grazia Giancipoli; Lorenzo Mannelli
Journal:  Radiol Oncol       Date:  2018-11-26       Impact factor: 2.991

8.  Gastric wall metastases from hepatocellular carcinoma: case report and review of the literature.

Authors:  Moheieldin M Abouzied; Ahmed Fathala; Ahmad AlMuhaideb; Hadeel Almanea; Abdulaziz S Al-Sugair; Rasha AlSkaff; Mohammed H Al-Qahtani
Journal:  Radiol Case Rep       Date:  2020-12-22

9.  2-[18F]FDG PET/CT as a Predictor of Microvascular Invasion and High Histological Grade in Patients with Hepatocellular Carcinoma.

Authors:  Aida Sabaté-Llobera; Judit Mestres-Martí; Gabriel Reynés-Llompart; Laura Lladó; Kristel Mils; Teresa Serrano; Montserrat Cortés-Romera; Esther Bertran; Isabel Fabregat; Emilio Ramos
Journal:  Cancers (Basel)       Date:  2021-05-23       Impact factor: 6.639

10.  68Ga-FAPI-04 Versus 18F-FDG PET/CT in the Detection of Hepatocellular Carcinoma.

Authors:  Hao Wang; Wenwei Zhu; Shuhua Ren; Yanyan Kong; Qi Huang; Jun Zhao; Yihui Guan; Huliang Jia; Jinhong Chen; Lu Lu; Fang Xie; Lunxiu Qin
Journal:  Front Oncol       Date:  2021-06-25       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.